SiNtx Technologies – Consensus Indicates Potential 147.5% Upside

Broker Ratings

SiNtx Technologies found using ticker (SINT) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 4.5 and 4.25 with the average target price sitting at 4.38. Now with the previous closing price of 1.77 this would imply there is a potential upside of 147.5%. The day 50 moving average is 1.8 and the 200 moving average now moves to 1.84. The company has a market capitalisation of $45m. Find out more information at: http://www.sintx.com

Sintx Technologies, a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. It offers ceramic based biomaterial solutions in various medical and industrial applications. The company provides spine implant products under the Valeo brand to surgeons and hospitals for use in cervical and thoracolumbar spine surgery. Sintx Technologies markets and sells its products directly; and through direct sales organizations, distributors, as well as original equipment manufacturer and private label partnerships. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies in October 2018. Sintx Technologies was founded in 1996 and is headquartered in Salt Lake City, Utah.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp